(1)在胰腺癌靶向治疗方面，提出靶向抑制CHKα联合mTOR治疗胰腺癌转移的新方案（Cancer Letters,2024）。
(2)在胰腺癌肝转移与免疫微环境方面，揭示NFE2驱动中性粒细胞极化促进胰腺癌肝转移进展的机制（Cell Reports,2025），系统综述肿瘤微环境与神经系统交互作用（BBA Reviews on Cancer,2024）及癌症肝转移免疫重塑（BBA Reviews on Cancer,2026）。

近5年代表性论著：
1) Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis. Cancer Letters. 2024. Nov 28;605:217280. (IF: 10.1)
2) NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. Cell Reports. 2025. Feb 25;44(2):115226. (IF: 7.5)
3) Tumor microenvironment crosstalk between tumors and the nervous system in pancreatic cancer: Molecular mechanisms and clinical perspectives. BBA Reviews on Cancer. 2024. Jan;1879(1):189032. (IF: 10.5)
4) Immune remodeling of liver metastases: From molecular mechanisms to therapeutic strategies. BBA Reviews on Cancer. 2026. Sep;1881(4):189618. (IF: 10.5)
5) NAMPT Modulates Gemcitabine Resistance in Pancreatic Cancer via the p53 Signaling Pathway. Pancreas. 2025. Aug 1;54(7):e575-e587. (IF: 1.9)